Arcturus Therapeutics Holdings Inc.
ARCTNasdaqCIK 1768224HealthcareFiscal year ends Dec 31
All transactions: 5
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2021-08-11 | Ultragenyx Pharmaceutical Inc.Director | Sale | 75,000 | $45.83 | $3.4m | Form 4 |
| 2021-08-10 | Ultragenyx Pharmaceutical Inc.Director | Sale | 725,000 | $55.44 | $40.2m | Form 4 |
| 2020-12-09 | Ultragenyx Pharmaceutical Inc.Director, 10% owner | Sale | 357,745 | $94.97 | $34.0m | Form 4 |
| 2020-12-08 | Ultragenyx Pharmaceutical Inc.Director, 10% owner | Sale | 442,255 | $105.54 | $46.7m | Form 4 |
| 2020-05-20 | Ultragenyx Pharmaceutical Inc.Director, 10% owner | Option exercise | 600,000 | $16.00 | $9.6m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 29, 2026, 06:06 ET. Listed shows no prices and gives no investment advice.